文献速递妇科

NK3R拮抗剂治疗绝经期潮热的兴起:一项叙述性综述

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review.
PubMed 文献 · BJOG · 2025-08-28

绝经期血管舒缩症状常见,约80%女性出现相关症状、25%为重度,激素治疗存在风险且部分患者不适用。综述汇总神经激肽B/NK3R通路在潮热发病中的作用及NK3R拮抗剂临床试验证据,非唑奈坦已在全球获批,每日中重度血管舒缩症状频率和严重度降低60%-80%,依林奈坦已在英国获批。

要点

  • 约80%女性经历绝经相关症状,25%为重度,最常见为血管舒缩症状(潮热和/或盗汗)。
  • 神经激肽B通过下丘脑NK3R信号参与绝经期血管舒缩症状的发生。
  • 非唑奈坦已获全球药品监管机构批准,试验显示每日中重度血管舒缩症状频率和严重度降低60%-80%。

核心结论

  • NK3R拮抗剂是靶向神经激肽B信号通路的非激素治疗选择,非唑奈坦已获全球药品监管机构批准,依林奈坦已获英国MHRA批准用于绝经期血管舒缩症状治疗、尚未获美国FDA批准。

研究设计与样本

  • 叙述性综述,汇总绝经期神经内分泌变化、动物与人类模型证据及NK3R拮抗剂临床试验数据。

主要发现

  • 约80%女性经历绝经相关症状,25%经历重度症状,最常见为血管舒缩症状(潮热和/或盗汗)。
  • 多项临床试验数据显示非唑奈坦使每日中重度血管舒缩症状的频率和严重度降低60%-80%,包括被认为不适合激素治疗者。
  • 依林奈坦已获英国MHRA批准用于绝经期血管舒缩症状治疗,尚未获美国FDA批准。

关键数值与推荐

  • 约80%女性经历绝经相关症状,25%经历重度症状。
  • 非唑奈坦使每日中重度血管舒缩症状频率和严重度降低60%-80%。

临床怎么用

  • 绝经激素治疗(MHT)是绝经相关症状最常用治疗,但部分治疗相关风险使其可能不适合所有女性,且部分接受MHT者症状未完全缓解。
  • 非唑奈坦已获全球药品监管机构批准,用于绝经期血管舒缩症状。
  • 依林奈坦已获英国MHRA批准用于绝经期血管舒缩症状治疗,尚未获美国FDA批准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats. Menopause hormone therapy (MHT) is the most common treatment for menopause-related symptoms; however, some treatment-related risks mean that MHT may not be suitable for all. Furthermore, following the publication of seminal studies, perceived risks of MHT have also led to reduced uptake. Additionally, not all women receiving MHT have full resolution of their symptoms. Therefore, alternative non-hormonal therapies are of therapeutic interest. Neurokinin B (NKB) signalling via its cognate receptor, neurokinin 3 receptor (NK3R), at the hypothalamus has been identified as a mediator of menopausal VMS. Recently, NK3R antagonists have been developed targeting the NKB signalling pathway as a novel effective non-hormonal therapeutic option for menopausal VMS. Fezolinetant has received approval from drug regulatory authorities worldwide, with data from multiple clinical trials showing a marked 60%-80% reduction in the frequency and severity of daily moderate-severe VMS, including in those considered unsuitable for MHT. Very recently, elinzanetant has been approved by the MHRA in the UK for the treatment of VMS in menopause, though it has not yet been approved by the FDA in the US. This review explores the neuroendocrine changes that occur in menopause and evidence from animal and human models suggesting that increased NKB signalling is involved in the pathogenesis of menopausal VMS. Data from clinical trials identifying NK3R antagonists as novel therapeutic agents for menopausal VMS are reviewed. Finally, the current status of NK3R antagonists and future directions of study in this area are discussed.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Patel AH, Pierret A, Mills EG, et al. Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review. BJOG. 2025. PMID: 40874287. doi:10.1111/1471-0528.18338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。